PLUS1
1.25
-0.04 (-3.1%)
-0.04 (-3.1%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Capricor Therapeutics Inc | CAPR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.13 | -9.15% | 1.29 | 1.20 | 1.39 | 1.39 | 1.42 | 00:00:07 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.20 | 1.43 | 0.23 | 16.08% | 1 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,729 | 1,168,711 | $ 1.30 | $ 1,521,224 | 1,015,603 | 0.2526 - 8.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:52:55 | 11 | $ 1.25 | USD |
Capricor Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 6.74M | 5.23M | $ -15.19M | -2.16 | - | 1.65M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Capricor Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/27/2020 | 08:32 | Edgar (US Regulatory) | Annual Report (10-k) |
| 3/26/2020 | 06:07 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/18/2020 | 16:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/18/2020 | 08:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/11/2020 | 06:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/18/2020 | 06:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/15/2020 | 01:04 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CAPR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.18 | 2.25 | 1.08 | 1.78 | 4,735,437 | 0.11 | 9.32% |
| 1 Month | 1.19 | 2.25 | 0.88 | 1.69 | 1,566,539 | 0.10 | 8.4% |
| 3 Months | 1.25 | 2.25 | 0.88 | 1.66 | 662,596 | 0.04 | 3.2% |
| 6 Months | 2.86 | 4.20 | 0.88 | 1.73 | 386,862 | -1.57 | -54.9% |
| 1 Year | 0.55 | 8.85 | 0.2526 | 3.36 | 460,806 | 0.74 | 134.55% |
| 3 Years | 3.37 | 8.85 | 0.2526 | 2.24 | 587,365 | -2.08 | -61.72% |
| 5 Years | 9.1079 | 9.52 | 0.2526 | 2.32 | 368,864 | -7.82 | -85.84% |
Capricor Therapeutics Description
| Capricor Therapeutics Inc is a United State-based clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, and other medical conditions. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. |
